Comparing Weight Management Strategies After Stopping GLP-1 Agonists

GLP-1 receptor agonists like semaglutide and tirzepatide have revolutionized obesity treatment, leading to significant weight loss. However, patients often experience substantial weight regain upon discontinuation, posing a major challenge for long-term weight management. This study addresses the urgent need to identify effective step-down treatment options to sustain weight loss after stopping GLP-1 therapies.

As this is an active trial and not yet recruiting, specific results are not available. However, the study is meticulously designed to quantify the absolute and percentage weight change in participants at 12 weeks post-discontinuation of GLP-1 agonists. Researchers aim to compare these crucial metrics across the different intervention groups to identify which strategy is most effective in preventing weight regain. This data will provide quantitative insights into the comparative effectiveness of behavioral, pharmacological, and combination therapies in maintaining weight loss. The primary outcome will be the absolute and percentage weight change measured at 12 weeks after participants stop taking semaglutide or tirzepatide.